Form 4: Natera Executive Solomon Moshkevich Sells Shares Under 10b5-1 Trading Plan

Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., sold a portion of his holdings in Natera common stock on April 1, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On April 1, 2025, Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., executed sales of Natera common stock.
• The sales were conducted under a Rule 10b5-1 trading plan adopted on November 26, 2024.
• A total of 3,000 shares were sold in multiple transactions at weighted average prices of $139.7757, $140.6959, and $141.8997.
• The sales resulted in a decrease in Moshkevich's direct holdings of Natera common stock, leaving him with 141,782 shares.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing regarding stock sales by an executive. It doesn't inherently convey positive or negative sentiment.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies. Rule 10b5-1 plans allow insiders to sell shares over a predetermined period, avoiding accusations of trading on non-public information.

Stakeholder Impact

• The stock sale may have a minor impact on shareholder sentiment, but is unlikely to have a significant effect given the pre-planned nature of the transactions.

Key Dates

Keywords

Natera, NTRA, Solomon Moshkevich, Insider Trading, Form 4, Rule 10b5-1, Stock Sale, Clinical Diagnostics